摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-amino-4-chloro-N-hydroxybenzamidine | 98280-45-6

中文名称
——
中文别名
——
英文名称
2-amino-4-chloro-N-hydroxybenzamidine
英文别名
2-amino-4-chloro benzamidoxime;2-amino-4-chloro-N'-hydroxybenzenecarboximidamide
2-amino-4-chloro-N-hydroxybenzamidine化学式
CAS
98280-45-6
化学式
C7H8ClN3O
mdl
——
分子量
185.613
InChiKey
KZYOXCBJFMGGIP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    84.6
  • 氢给体数:
    3
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    参考文献:
    名称:
    对3-(酰基氨基)-1H-吲唑的合成研究和一锅微波辅助的恶二唑缩合/ Boulton-Katritzky重排的发展
    摘要:
    对3-(2-氨基芳基)-1,2,4-恶二唑的Boulton-Katritzky重排的研究导致确定了控制重排以及选择底物竞争性热重排途径的其他电子因素。为了避免常规热转化序列的局限性,已设计出一种采用微波辐射的改进方案,该方案允许以良好的分离产率良好地获得重排产物。此外,我们已经开发了一种使用微波辅助的恶二唑缩合/ Boulton-Katritzky重排的两组分,一锅法序列,以从简单的酯和2-氨基-N-羟基-生成3-(酰基氨基)-1 H-吲唑。苯甲idine Boulton-Katritzky重排-吲唑-微波辅助-恶二唑缩合-取代基效应
    DOI:
    10.1055/s-0031-1289893
  • 作为产物:
    描述:
    2-氨基-4-氯苯腈盐酸羟胺碳酸氢钠 作用下, 以 乙醇 为溶剂, 以35%的产率得到2-amino-4-chloro-N-hydroxybenzamidine
    参考文献:
    名称:
    独立于底物的高通量定量醛
    摘要:
    通过化学方法将羧酸选择性和直接还原成相应的醛仍然是合成中的挑战性任务。已知有几种还原和氧化化学方法可产生醛,但大多数方法需要昂贵的试剂,特殊的反应条件,分两步操作且通常缺乏化学选择性。大自然提供了一种优雅的工具,即所谓的羧酸还原酶(CARs),用于将羧酸直接还原为醛。新型CAR酶的发现和工程化需要强大的产品选择性高通量分析(HTA)。我们报告了一种简单而快速的HTA,它允许醛的底物独立和化学选择性定量(无论其化学结构如何),并且对nM范围敏感。爱欧诺卡氏菌(CAR Ni)。结果与报道的数据完全一致。
    DOI:
    10.1002/adsc.201900154
点击查看最新优质反应信息

文献信息

  • Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof
    申请人:——
    公开号:US20030045546A1
    公开(公告)日:2003-03-06
    The present invention is directed to substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs thereof, represented by the Formula I: 1 wherein Ar 1 , Ar 3 , A, B and D are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    本发明涉及取代的3-芳基-5-芳基-[1,2,4]-噁二唑及其类似物,由以下式I表示: 1 其中Ar1,Ar3,A,B和D在此处定义。本发明还涉及发现具有式I的化合物是caspase的激活剂和凋亡诱导剂。因此,本发明的caspase激活剂和凋亡诱导剂可用于诱导在各种临床病况中发生未受控制的异常细胞生长和扩散的细胞死亡。
  • Identification of potent and selective small molecule inhibitors of the cation channel TRPM4
    作者:Lijo Cherian Ozhathil、Clémence Delalande、Beatrice Bianchi、Gabor Nemeth、Sven Kappel、Urs Thomet、Daniela Ross-Kaschitza、Céline Simonin、Matthias Rubin、Jürg Gertsch、Martin Lochner、Christine Peinelt、Jean-Louis Reymond、Hugues Abriel
    DOI:10.1111/bph.14220
    日期:2018.6
    and has not yet been validated as a therapeutic target due to the lack of potent and selective inhibitors. We sought to discover a novel series of small-molecule inhibitors by combining in silico methods and cell-based screening assay, with sub-micromolar potency and improved selectivity from previously reported TRPM4 inhibitors. EXPERIMENTAL APPROACH Here, we developed a high throughput screening compatible
    背景和目的 TRPM4 是一种钙激活的非选择性阳离子通道,在许多组织中表达,与多种疾病有关,由于缺乏有效的选择性抑制剂,尚未被验证为治疗靶点。我们试图通过结合计算机方法和基于细胞的筛选测定来发现一系列新型小分子抑制剂,其具有亚微摩尔效力,并且比之前报道的 TRPM4 抑制剂具有更高的选择性。实验方法在这里,我们开发了一种高通量筛选兼容测定法,使用 Na+ 敏感染料记录细胞中 TRPM4 介导的 Na+ 流入,并使用该测定法筛选通过使用先前已知的弱活性的基于配体的虚拟筛选选择的一小组化合物和非选择性 TRPM4 抑制剂作为种子分子。使用常规电生理学方法来验证命中化合物在过表达 TRPM4 的 HEK293 细胞和内源表达前列腺癌细胞系 LNCaP 中的效力和选择性。使用蛋白质印迹和电生理学实验研究了化合物 5 的化学伴侣特性。主要结果 一系列卤代邻氨基苯甲酰胺被鉴定为具有 TRPM4 抑制特
  • Bioisosteric Modifications of 2-Arylureidobenzoic Acids:  Selective Noncompetitive Antagonists for the Homomeric Kainate Receptor Subtype GluR5
    作者:Jon Valgeirsson、Elsebet Ø. Nielsen、Dan Peters、Claus Mathiesen、Anders S. Kristensen、Ulf Madsen
    DOI:10.1021/jm030638w
    日期:2004.12.1
    2-Arylureidobenzoic acids (AUBAs) have recently been presented as the first series of selective noncompetitive GluR5 antagonists. In this paper we have modified the acidic moiety of the AUBAs by introducing different acidic and neutral groups, and similarly, we have replaced the urea linker of the AUBAs with other structurally related linkers. Replacing the acid with neutral substituents led to inactive compounds in all instances, showing that an acidic moiety is necessary for activity. Replacing the carboxylic moiety in 2a with a sulfonic acid (5c) or a tetrazole ring (5d) improved the potency at GluR5 receptors (compounds 5c and 5d showed IC50 values of 1.5 and 2.0 muM, respectively, compared to compound 2a with IC50 = 4.8 muM). Compound 5c did not show improved in vivo activity in the ATPA rigidity test compared to 2a, whereas compound 5d was 4 times more potent than 2a. All compounds wherein the urea linker had been replaced showed lower or no activity. The results described extend the knowledge of structure-activity relationships for the AUBAs, and compound 5d may prove to be a good candidate for studying GluR5 receptors in vitro and in vivo.
  • Discovery of 3-aryl-5-aryl-1,2,4-oxadiazoles as a new series of apoptosis inducers. 2. Identification of more aqueous soluble analogs as potential anticancer agents
    作者:William Kemnitzer、Jared Kuemmerle、Han-Zhong Zhang、Shailaja Kasibhatla、Ben Tseng、John Drewe、Sui Xiong Cai
    DOI:10.1016/j.bmcl.2009.05.052
    日期:2009.8
    As a continuation of our efforts to discover and develop the 3-aryl-5-aryl-1,2,4-oxadiazole series of apoptosis inducers as potential anticancer agents, we explored substitutions at the 2-and 3-positions of the 3-aryl group to improve the aqueous solubility properties and identify development candidates. A small substitution such as methyl or hydroxymethyl at the 2-position was well tolerated. This modification, in combination with a 3-substituted furan ring as the 5-aryl group, resulted in 4g and 4h, which have improved solubility properties. Compound 4g was found to have good in vivo efficacy in animal studies via intravenous administration. (C) 2009 Elsevier Ltd. All rights reserved.
  • Carrington, Journal of the Chemical Society, 1955, p. 2527
    作者:Carrington
    DOI:——
    日期:——
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐